10x Genomics Inc. and the A*STAR Genome Institute of Singapore have announced the launch of the TISHUMAP study, a collaborative research initiative aimed at advancing AI-driven drug target discovery. This study will utilize 10x Genomics' Xenium platform to analyze up to 2,500 formalin-fixed paraffin-embedded (FFPE) clinical tissue samples, focusing on cancers such as gastric, liver, and colorectal. The goal is to uncover novel biomarkers and therapeutic targets for cancer and inflammatory diseases by creating a comprehensive molecular-level map of gene activity within intact tissues. This collaboration is expected to significantly enhance the identification of new diagnostics and potential personalized treatment plans, although specific results from the study have not been presented yet.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.